Skip to main content
OpenTrials
Completed

NCT Number: NCT07673432

A Clinical Trial to Evaluate the Effects of a Plant-Based Liquid Supplement on Metabolic Health and Overall Well-Being

This single-arm clinical trial will evaluate the effects of a plant-based liquid supplement on metabolic health, digestive health, skin health, and overall well-being. Twenty participants aged 40 to 60 years with elevated alanine transaminase (ALT) or aspartate transaminase (AST) levels will use the supplement daily for 90 days. Participants will complete questionnaires, provide body composition and waist circumference measurements, submit photographs, and undergo blood testing throughout the study. Outcomes include changes in metabolic biomarkers, body composition, digestive symptoms, skin health, and overall well-being.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Metabolic Health Digestive Symptoms Elevated Liver Enzymes

Age range

40 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Citruslabs

Las Vegas, Nevada, 89118, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 40 to 60 years
  • Elevated ALT or AST identified during prescreening blood testing
  • Currently experiencing at least two of the following:

Stomach discomfort, Constipation, Diarrhea, Heartburn, Bloating, Gas, Abdominal pain, Skin redness or pimples, Sugar cravings

  • Willing to comply with study requirements
  • Willing to discontinue supplements or herbal remedies targeting detoxification, digestive health, liver function, or skin health during the study
  • Willing to avoid starting new products, medications, or supplements targeting detoxification, digestive health, liver function, or skin health
  • Willing to maintain normal diet, sleep patterns, and activity levels
  • Generally healthy without uncontrolled chronic disease
  • Resides in the United States
  • Not participating in another research study during the study period
  • Has access to a study partner to take study photographs

Exclusion criteria

  • Severe digestive disorders including acid reflux, IBS, IBD, Crohn's disease, or gastrointestinal tract surgeries
  • Liver disease
  • Known allergy or hypersensitivity to study product ingredients Chronic conditions that would interfere with study participation, including oncological or psychiatric disorders
  • Known severe allergic reactions
  • Pregnant, breastfeeding, or attempting to conceive
  • Unwilling to follow study procedures
  • Stopped hormonal birth control within the past month
  • History of substance abuse
  • Use of prescription diabetes medications, including GLP-1 receptor agonists such as Ozempic, Wegovy, or Mounjaro

Treatment and study plan

Plant-Based Liquid Supplement

Dietary Supplement

A liquid dietary supplement containing choline bitartrate, zinc sulfate, manganese sulfate, artichoke leaf extract, fennel extract, rosemary leaf extract, L-arginine monohydrochloride, inositol, bromelain, papain, sorbitol, glycerin, artificial flavour, and potassium sorbate.

Primary outcomes

  1. Change in Body Weight

    Time frame: Baseline, Day 30, Day 60, and Day 90.

    Change in body weight measured using a Withings smart scale.

  2. Change in Waist Circumference

    Time frame: Baseline, Day 7, Day 30, Day 60, and Day 90.

    Change in waist circumference measured using a tape measure and recorded in centimeters.

  3. Change in Body Fat Mass

    Time frame: Baseline, Day 7, Day 30, Day 60, and Day 90.

    Change in body fat mass measured using a Withings smart scale.

  4. Change in Lean Body Mass

    Time frame: Baseline, Day 7, Day 30, Day 60, and Day 90.

    Change in lean body mass measured using a Withings smart scale.

  5. Change in Visceral Fat Index

    Time frame: Baseline, Day 7, Day 30, Day 60, and Day 90.

    Change in visceral fat index measured using a Withings smart scale.

  6. Change in Alanine Aminotransferase (ALT)

    Time frame: Baseline, Day 30, Day 60, and Day 90.

    Change in serum alanine aminotransferase concentration measured by hepatic function panel.

  7. Change in Aspartate Aminotransferase (AST)

    Time frame: Baseline, Day 30, Day 60, and Day 90

    Change in serum aspartate aminotransferase concentration measured by hepatic function panel.

  8. Change in Alkaline Phosphatase (ALP)

    Time frame: Baseline, Day 30, Day 60, and Day 90.

    Change in serum alkaline phosphatase concentration measured by hepatic function panel.

  9. Change in Total Bilirubin

    Time frame: Baseline, Day 30, Day 60, and Day 90.

    Change in serum total bilirubin concentration measured by hepatic function panel.

  10. Change in Total Cholesterol

    Time frame: Baseline, Day 30, Day 60, and Day 90.

    Change in serum total cholesterol concentration measured by lipid panel.

Secondary outcomes

  1. Change in Participant-Reported Bloating Severity

    Time frame: Baseline, Day 1, Day 3, Day 7, Day 30, Day 60, and Day 90.

    Change in participant-reported bloating severity assessed by study questionnaire.

  2. Change in Participant-Reported Flatulence Severity

    Time frame: Baseline, Day 1, Day 3, Day 7, Day 30, Day 60, and Day 90.

    Change in participant-reported flatulence severity assessed by study questionnaire.

  3. Change in Participant-Reported Heartburn Severity

    Time frame: Baseline, Day 1, Day 3, Day 7, Day 30, Day 60, and Day 90.

    Change in participant-reported heartburn severity assessed by study questionnaire.

  4. Change in Participant-Reported Digestive Comfort

    Time frame: Baseline, Day 1, Day 3, Day 7, Day 30, Day 60, and Day 90.

    Change in participant-reported digestive comfort assessed by study questionnaire.

  5. Change in Participant-Reported Skin Health

    Time frame: Baseline, Day 1, Day 3, Day 7, Day 30, Day 60, and Day 90.

    Change in participant-reported skin health assessed by study questionnaire.

Sponsors and collaborators

Lead sponsor

Biocol Labs

Industry

Collaborators

  • Citruslabs

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jun 29, 2026
Registry last updated
Jun 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.